Michele Reni

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. ncbi request reprint New therapies for pancreatic cancer: current standard
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute Milan, Italy
    JOP 8:98-101. 2007
  2. doi request reprint Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial
    Michele Reni
    S Raffaele Scientific Institute, Milan, Italy Electronic address
    Eur J Cancer 49:3609-15. 2013
  3. doi request reprint Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Ann Surg Oncol 19:2256-63. 2012
  4. ncbi request reprint Evidences and opinions for adjuvant therapy in pancreatic cancer
    Michele Reni
    Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Curr Drug Targets 13:789-94. 2012
  5. ncbi request reprint Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial
    Michele Reni
    Department of Radiochemotherapy, S Raffaele Hospital Scientific Institute, Milan, Italy
    Eur J Cancer 40:1682-8. 2004
  6. ncbi request reprint Ependymoma
    Michele Reni
    Medical Oncology Unit, San Raffaele Scientific Institute, Milan, Italy
    Crit Rev Oncol Hematol 63:81-9. 2007
  7. ncbi request reprint PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen
    M Reni
    Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Cancer Lett 256:25-8. 2007
  8. ncbi request reprint Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study
    M Reni
    Department of Oncology, S Raffaele H Scientific Institute, Milan, Italy
    Cancer Invest 25:594-8. 2007
  9. ncbi request reprint A multicenter study of the prognosis and treatment of adult brain ependymal tumors
    Michele Reni
    Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy
    Cancer 100:1221-9. 2004
  10. ncbi request reprint Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate
    Michele Reni
    Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Cancer Lett 258:165-70. 2007

Detail Information

Publications96

  1. ncbi request reprint New therapies for pancreatic cancer: current standard
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute Milan, Italy
    JOP 8:98-101. 2007
  2. doi request reprint Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial
    Michele Reni
    S Raffaele Scientific Institute, Milan, Italy Electronic address
    Eur J Cancer 49:3609-15. 2013
    ..This open-label, randomised, multi-centre phase II trial explored the role of maintenance sunitinib after first-line chemotherapy in this setting...
  3. doi request reprint Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Ann Surg Oncol 19:2256-63. 2012
    ..This randomized phase II trial aimed to identify the most promising regimen warranting phase III evaluation...
  4. ncbi request reprint Evidences and opinions for adjuvant therapy in pancreatic cancer
    Michele Reni
    Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Curr Drug Targets 13:789-94. 2012
    ..The need for more active and effective systemic treatments, for a better knowledge of the disease biology, for new therapeutic agents and predictors of pattern of recurrence is evident...
  5. ncbi request reprint Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial
    Michele Reni
    Department of Radiochemotherapy, S Raffaele Hospital Scientific Institute, Milan, Italy
    Eur J Cancer 40:1682-8. 2004
    ..Although some patients had a poor PS and had been heavily pre-treated, temozolomide yielded 26% objective responses and was well tolerated without any major toxicity...
  6. ncbi request reprint Ependymoma
    Michele Reni
    Medical Oncology Unit, San Raffaele Scientific Institute, Milan, Italy
    Crit Rev Oncol Hematol 63:81-9. 2007
    ..There is no proof that postoperative chemotherapy improves the outcome. At recurrence, platinum-, nitrosourea- or temozolomide-based chemotherapy can be administered, although there is no evidence of efficacy...
  7. ncbi request reprint PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen
    M Reni
    Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Cancer Lett 256:25-8. 2007
    ..Results of other recent trials comparing gemcitabine-erlotinib, gemcitabine-capecitabine and gemcitabine-oxaliplatin combinations to single agent gemcitabine are briefly commented from a clinical perspective...
  8. ncbi request reprint Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study
    M Reni
    Department of Oncology, S Raffaele H Scientific Institute, Milan, Italy
    Cancer Invest 25:594-8. 2007
    ....
  9. ncbi request reprint A multicenter study of the prognosis and treatment of adult brain ependymal tumors
    Michele Reni
    Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy
    Cancer 100:1221-9. 2004
    ....
  10. ncbi request reprint Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate
    Michele Reni
    Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Cancer Lett 258:165-70. 2007
    ..High-dose chemotherapy supported by stem cell autotransplant and intrathecal chemotherapy in meningeal failure have to be further investigated in prospective trials...
  11. doi request reprint A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma
    M Reni
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
    Cancer Chemother Pharmacol 62:673-8. 2008
    ..Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment...
  12. pmc Temozolomide as salvage treatment in primary brain lymphomas
    M Reni
    Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Br J Cancer 96:864-7. 2007
    ..Toxicity was negligible. We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment...
  13. ncbi request reprint Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial
    Michele Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Cancer Invest 22:688-96. 2004
    ..This study evaluates the maximum tolerated dose (MTD) and activity of mitomycin, docetaxel, and irinotecan (MDI) regimen on metastatic pancreatic adenocarcinoma, previously treated with gemcitabine-containing chemotherapy...
  14. ncbi request reprint Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Pancreatology 6:454-63. 2006
    ..The analysis of treatment impact on quality of life (QOL) is reported...
  15. ncbi request reprint Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
    M Reni
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
    Cancer Chemother Pharmacol 59:361-7. 2007
    ..Results of a consecutive series treated by dose-intense PEFG regimen are herewith reported...
  16. pmc Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
    M Reni
    Department of Oncology, S Raffaele Hsc Scientific Inst, Via Olgettina 60, 20132 Milan, Italy
    Br J Cancer 94:785-91. 2006
    ..Previous PFS interval may allow the identification of patients who are more likely to benefit from salvage treatment...
  17. ncbi request reprint Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Lancet Oncol 6:369-76. 2005
    ..We aimed to assess whether a four-drug regimen could improve 4 month progression-free survival compared with gemcitabine alone...
  18. ncbi request reprint Novel therapeutics in adult malignant brain gliomas
    Michele Reni
    Department of Oncology, San Raffaele H Scientific Institute via Olgettina 60, 20132 Milan
    Expert Opin Investig Drugs 14:643-58. 2005
    ....
  19. doi request reprint PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy
    M Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Am J Clin Oncol 31:145-50. 2008
    ..The activity and safety of this combination regimen were assessed by means of an observational study in a population of patients with progressive or recurrent pancreatic adenocarcinoma after gemcitabine-containing chemotherapy...
  20. doi request reprint Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Cancer 115:2630-9. 2009
    ..The objective of this study was to evaluate the correlation between a decline in carbohydrate antigen 19-9 (CA 19-9) and survival in patients with advanced pancreatic cancer who received upfront chemotherapy...
  21. doi request reprint A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
    Michele Reni
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Cancer Chemother Pharmacol 69:115-23. 2012
    ..The current trial was aimed at assessing whether the replacement of E with docetaxel (D) may improve 6 months PFS (PFS6)...
  22. doi request reprint Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
    Michele Reni
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy
    Dig Liver Dis 43:225-30. 2011
    ..Since gemcitabine became the standard treatment for metastatic pancreatic adenocarcinoma, combination chemotherapy obtained conflicting impact on survival (OS)...
  23. ncbi request reprint Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma
    M Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Int J Radiat Oncol Biol Phys 50:651-8. 2001
    ..To assess the impact on local control and survival of intraoperative radiotherapy (IORT) in resectable pancreatic adenocarcinoma...
  24. ncbi request reprint Irradiation fields and doses in glioblastoma multiforme: are current standards adequate?
    M Reni
    Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy
    Tumori 87:85-90. 2001
    ..To better characterize a standard radiotherapy in glioblastoma multiforme, the impact on survival of different fields and doses was analyzed in a retrospective single center series...
  25. ncbi request reprint Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate
    M Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Int J Radiat Oncol Biol Phys 51:419-25. 2001
    ..To evaluate the optimal dose of methotrexate (MTX) and the efficacy of other drugs, intrathecal chemotherapy (CHT), and radiotherapy (RT) in primary brain lymphomas...
  26. ncbi request reprint Therapeutic management of refractory or relapsed primary central nervous system lymphomas
    M Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Ann Hematol 80:B113-7. 2001
    ..Finally, the inclusion of relapsing or progressive PCNSL patients into second-line prospective clinical trials for testing therapeutic agents should be strongly encouraged...
  27. ncbi request reprint Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Oncology 68:239-45. 2005
    ..Postoperative management of patients with pancreatic adenocarcinoma (PA) is controversial...
  28. doi request reprint An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
    Michele Reni
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy
    Anticancer Drugs 21:459-64. 2010
    ....
  29. ncbi request reprint Therapeutic management of primary CNS lymphoma in immunocompetent patients
    M Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Expert Rev Anticancer Ther 1:382-94. 2001
    ..Finally, the main open questions as well as current and expected investigation trends are discussed...
  30. doi request reprint Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
    Cancer Chemother Pharmacol 64:1253-9. 2009
    ..The role and timing of chemotherapy and radiation for treating stage III pancreatic adenocarcinoma remains controversial...
  31. ncbi request reprint Current management and prognostic factors for adult ependymoma
    Michele Reni
    Department of Radiochemotherapy, San Raffael H Scientific Institute via Olgettina 60, 20132 Milan, Italy
    Expert Rev Anticancer Ther 2:537-45. 2002
    ..Some important therapeutic issues like the irradiation dose and volume are also analyzed. Finally, the main open questions as well as current and expected investigation trends are discussed...
  32. doi request reprint Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study
    Paolo Passoni
    Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy Electronic address
    Int J Radiat Oncol Biol Phys 87:1000-6. 2013
    ....
  33. pmc Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination
    Andres J M Ferreri
    Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Oncologist 16:336-41. 2011
    ..With respect to MTX-araC combination, araC dose was halved to minimize toxicity. Herein, we report tolerability, activity, and efficacy of MAT regimen and compare these results to those previously reported with MTX/ara-C combination...
  34. ncbi request reprint XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer
    Stefano Cereda
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Anticancer Res 30:4785-90. 2010
    ..More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they experience upfront treatment failure...
  35. doi request reprint Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial
    Stefano Cereda
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Chemotherapy 57:156-61. 2011
    ..At the time of upfront treatment failure, over half of the patients with advanced pancreatic cancer are candidates for further treatment...
  36. doi request reprint Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy
    Andrés José María Ferreri
    Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Int J Radiat Oncol Biol Phys 80:169-75. 2011
    ..Nevertheless, no study has focused on the survival impact of radiation parameters, as far as we know, and the optimal radiation schedule remains to be defined...
  37. doi request reprint Treatment approaches for primary CNS lymphomas
    Matteo G Carrabba
    San Raffaele Scientific Institute, Haematology and Bone Marrow Transplantation Unit, Department of Oncology, Milan, Italy
    Expert Opin Pharmacother 11:1263-76. 2010
    ..The overall outcome for PCNSL patients is unsatisfactory and several therapeutic questions remain open. Modest progress in outcome reflects difficulties in conducting randomized trials and scarce molecular and biological knowledge...
  38. doi request reprint Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy
    Nicolò Pecorelli
    Department of Surgery, Vita Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
    J Gastrointest Surg 17:488-93. 2013
    ..The objective of this study is to assess the impact of PCHT on pancreatic structure and short-term outcome after surgical resection...
  39. doi request reprint High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
    Lancet 374:1512-20. 2009
    ..We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma...
  40. doi request reprint The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma
    Stefano Cereda
    Medical Oncology Unit Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Cancer 116:2208-14. 2010
    ..In this study, the authors assessed the activity and safety of this combination regimen in patients with advanced BTA...
  41. ncbi request reprint Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience
    Andres J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    J Clin Oncol 21:266-72. 2003
    ..To identify survival predictors and to design a prognostic score useful for distinguishing risk groups in immunocompetent patients with primary CNS lymphomas (PCNSL)...
  42. ncbi request reprint The role of intraoperative therapy by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas
    V Fossati
    Radiation-Oncology Department, Istituto Nazionale Tumori, Milan, Italy
    Tumori 81:23-31. 1995
    ..In resected patients, IORT is effective in decreasing local recurrences but has little impact on survival. To obtain more satisfactory results, new and more effective adjuvant therapies and better abdominal prophylaxis should be tested...
  43. ncbi request reprint Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma
    M Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institution, Milan, Italy
    J Clin Oncol 19:2679-86. 2001
    ..To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma...
  44. ncbi request reprint Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas
    Andres J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Br J Haematol 126:657-64. 2004
    ..If confirmed in prospective trials on PCNSL treated with HD-MTX alone, these data may suggest the necessity for alternative strategies in M-PCNSL considering the increased risk of MTX resistance by tumour cells...
  45. doi request reprint Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer
    Paolo Giorgio Arcidiacono
    Division of Gastroenterology and Gastrointestinal Endoscopy, Vita Salute San Raffaele University Scientific Institute San Raffaele, Milan, Italy
    Gastrointest Endosc 76:1142-51. 2012
    ..New therapies are needed for pancreatic cancer...
  46. ncbi request reprint Questions and answers in the management of primary central nervous system and ocular lymphomas
    Andres J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Haematologica 88:1063-8. 2003
  47. ncbi request reprint Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis
    Giovanni Luca Ceresoli
    Department of Radiochemotherapy, IRCCS San Raffaele, Via Olgettina 60, 02132 Milan, Italy
    Cancer 95:605-12. 2002
    ..New treatment and follow-up strategies are needed to reduce the risk of BM and to diagnose them early enough for effective treatment...
  48. doi request reprint High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Leuk Lymphoma 49:2042-7. 2008
    ..This critical review is focused on the analysis of published experiences on HDC/ASCT in PCNSL in order to provide preliminary answers to the most pressing questions in this field...
  49. doi request reprint Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system
    Jody Filippo Capitanio
    Department of Neurosurgery and Radiosurgery, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Crit Rev Oncol Hematol 86:69-84. 2013
    ..This strategy warrants prospective evaluation in a clinical trial...
  50. ncbi request reprint Prognostic factors in primary central nervous system lymphomas
    Andres J M Ferreri
    Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Hematol Oncol Clin North Am 19:629-49, vi. 2005
    ..In the years ahead, a well-established prognostic score will allow the separation of patients into risk groups, which could result in the application of risk-tailored therapeutic strategies...
  51. pmc Second-line treatment for primary central nervous system lymphoma
    M Reni
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Br J Cancer 79:530-4. 1999
    ..Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule...
  52. doi request reprint Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma
    Giovanni M Cattaneo
    Medical Physics Department, San Raffaele Scientific Institute, Milan, Italy
    Radiother Oncol 108:66-71. 2013
    ..A better understanding of the influence of dosimetric variables on the rate of toxicity after RT must be considered an important goal...
  53. doi request reprint Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors
    Sara Madaschi
    Endocrinology Unit, Department of Internal Medicine, San Raffaele Scientific Institute, Milan, Italy
    Radiother Oncol 99:23-8. 2011
    ..No longitudinal data on hypothalamic-pituitary (HP) function are available in patients who had received cranial radiation therapy (CRT) for primary extrasellar brain tumors (PBT)...
  54. doi request reprint Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies
    Giulia Sangalli
    Medical Physics Department, San Raffaele Scientific Institute, Milan, Italy
    Acta Oncol 50:72-80. 2011
    ..to study the impact of the 4DCT imaging technique on radiotherapy planning for pancreatic carcinoma. To evaluate the possibility of IMRT/IGRT to increase the dose to PTV subvolume...
  55. ncbi request reprint Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    S Cereda
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    J Chemother 20:509-12. 2008
    ..5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer...
  56. doi request reprint Second-line therapy in advanced biliary tract cancer: what should be the standard?
    Stefano Cereda
    Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy Electronic address
    Crit Rev Oncol Hematol 88:368-74. 2013
    ..Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy. ..
  57. doi request reprint Neoadjuvant therapy in resectable pancreatic cancer: a critical review
    Carmen Belli
    Department of Medical Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Cancer Treat Rev 39:518-24. 2013
    ..In this scenario, the neoadjuvant approach has a strong theoretical rationale, but limited information on the efficacy of this strategy is available...
  58. doi request reprint Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma
    Giuseppe Aprile
    Department of Oncology, University Hospital S Maria della Misericordia of Udine, Piazzale S Maria della Misericordia, 33100, Udine, Italy
    Tumour Biol 34:131-7. 2013
    ..Rather, we underline the complexity of tumor-stroma interactions in the advanced stage of cancer and the need of further study...
  59. ncbi request reprint Primary central nervous system lymphoma
    Andres J M Ferreri
    Medical Oncology Unit, San Raffaele Scientific Institute, Milan, Italy
    Crit Rev Oncol Hematol 63:257-68. 2007
    ..Although studies published on PCNSL are increasing, several therapeutic questions still remain unanswered after a decade of research...
  60. ncbi request reprint A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile
    Paolo Monti
    Laboratory of Experimental Surgery, Department of Diabetes and Transplant Immunology, S Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Virchows Arch 445:236-47. 2004
    ..In conclusion, a clear correlation between structural/genetic features and function could not be detected, suggesting the weakness of a "morphological" classification for the in vitro studies of pancreatic cancer...
  61. doi request reprint Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases
    Marco Losa
    Pituitary Unit, Department of Neurosurgery, Istituto Scientifico San Raffaele, Universita Vita Salute, Via Olgettina 60, 20132 Milano, Italy
    Eur J Endocrinol 163:843-51. 2010
    ..We assessed the efficacy of treatment with temozolomide, an oral second-generation alkylating agent, in a consecutive series of six patients with aggressive pituitary adenomas...
  62. ncbi request reprint Target delineation in post-operative radiotherapy of brain gliomas: interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans
    Giovanni Mauro Cattaneo
    Medical Physics, Scientific Institute, H S Raffaele, Milano, Italy
    Radiother Oncol 75:217-23. 2005
    ..To investigate the interobserver variability of intracranial tumour delineation on computed tomography (CT) scans using pre-operative MR hardcopies (CT+MR(conv)) or CT-MR (pre-operative) registered images (CT+MR(matched))...
  63. doi request reprint Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma
    Pietro Mancosu
    Scientific Institute H San Raffaele, Milano, Italy
    Radiother Oncol 87:339-42. 2008
    ..The procedure allows good quality images to be obtained over the whole patient's breathing cycle in terms of anatomical details, pancreatic enhancement and vessel definition...
  64. ncbi request reprint Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials
    A J Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Ann Oncol 11:927-37. 2000
    ..The assessment of impact of treatment on neuropsychological functions and quality of life is a mandatory endpoint in clinical trials...
  65. ncbi request reprint Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients
    A J Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Oncology 60:134-40. 2001
    ..Patients who achieved a complete remission were referred to RT, those with progressive disease were excluded from further study; all the remaining patients received a third course of CHT followed by RT...
  66. ncbi request reprint MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
    A J M Ferreri
    Medical Oncology Unit, San Raffaele H Scientific Institute, Universita Vita Salute San Raffaele, Milan, Italy
    Neurology 66:1435-8. 2006
    ..Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained...
  67. ncbi request reprint Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas
    A J Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Oncology 58:219-26. 2000
    ..To assess the impact on survival of consolidation radiotherapy to bulky or semibulky lesions in patients with advanced diffuse large B cell lymphoma (DLCL) in complete remission after primary chemotherapy...
  68. ncbi request reprint A multicenter study of treatment of primary CNS lymphoma
    A J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Neurology 58:1513-20. 2002
    ..To characterize the therapeutic variables correlated to outcome in 370 patients with primary CNS lymphoma...
  69. ncbi request reprint Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
    M Ponzoni
    Pathology Unit, Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
    Br J Haematol 138:316-23. 2007
    ..In conclusion, the presence of RPVI is independently associated with survival in PCNSL. This parameter can be easily and routinely assessed at diagnosis on histopathological specimens...
  70. ncbi request reprint Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin's lymphoma of bone in adults
    A J Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Cancer Invest 16:554-61. 1998
    ..Patients with multiple adjacent lesions that can be included within a single radiation field with acceptable toxicity should be treated as cases of monostotic PLB...
  71. ncbi request reprint Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases
    A Carretta
    Department of Thoracic Surgery, Scientific Institute H San Raffaele, University of Milan, Via Olgettina, 60 20132, Milan, Italy
    Lung Cancer 29:217-25. 2000
    ..The prognostic role of biological factors such as cytometry and genetic markers requires further investigation before any definitive conclusions can be drawn...
  72. ncbi request reprint Relevance of intraocular involvement in the management of primary central nervous system lymphomas
    A J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Ann Oncol 13:531-8. 2002
    ..Reported data regarding intraocular lymphoma (IOL) management are anecdotal. Cases of IOL included in an international multicentre series of 378 immunocompetent patients with primary central nervous system lymphomas (PCNSLs) were reviewed...
  73. pmc Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas
    A J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, Milan 20132, Italy
    Br J Cancer 90:353-8. 2004
    ..MTX dose adjustments in patients with fast CL(crea) should be investigated...
  74. doi request reprint Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy
    Silvia Mappa
    Unit of Lymphoid Malignancies, Division of Onco Hematological Medicine, Department of Onco Hematology, San Raffaele Scientific Institute, Milan, Italy
    Hematol Oncol 31:143-50. 2013
    ..This regimen allows stem cell collection and successful consolidation with high-dose chemotherapy and autologous transplant. Copyright © 2012 John Wiley & Sons, Ltd. ..
  75. doi request reprint Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour
    Filippo Gagliardi
    Department of Neurosurgery, San Raffaele Scientific Institute, Vita Salute University, Milan, Italy
    Acta Neurochir (Wien) 155:1849-56. 2013
    ..Clival solitary plasmocytomas have been described only as single case reports or included in small clinical series with other intracranial location...
  76. pmc Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
    Lucia De Monte
    Tumor Immunology Unit, San Raffaele Scientific Institute, 20132 Milan, Italy
    J Exp Med 208:469-78. 2011
    ..Thus, blocking TSLP production by CAFs might help to improve prognosis in pancreatic cancer...
  77. pmc Role of taxanes in pancreatic cancer
    Carmen Belli
    Carmen Belli, Stefano Cereda, Michele Reni, Department of Oncology, San Raffaele Scientific Institute, 20132 Milan, Italy
    World J Gastroenterol 18:4457-65. 2012
    ..Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings...
  78. pmc Adjuvant treatment in biliary tract cancer: To treat or not to treat?
    Stefano Cereda
    Stefano Cereda, Carmen Belli, Michele Reni, Department of Oncology, San Raffaele Scientific Institute, 20132 Milan, Italy
    World J Gastroenterol 18:2591-6. 2012
    ..Well-designed multi-institutional randomized trials are necessary to clarify the role of adjuvant therapy. Two ongoing phase III trials may provide relevant information...
  79. pmc A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
    A Mercalli
    Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
    Br J Cancer 96:1358-67. 2007
    ..The PMX and CPT-11 combination displays a strong schedule-independent synergistic cytotoxic activity against pancreatic cancer, providing experimental basis for its clinical testing as salvage chemotherapy in pancreatic cancer patients...
  80. doi request reprint Current uses of radiation therapy in patients with primary CNS lymphoma
    Giovanni Citterio
    Department of Onco Hematology, San Raffaele Scientific Institute, Milano, Italy
    Expert Rev Anticancer Ther 13:1327-37. 2013
    ..In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity. ..
  81. ncbi request reprint Quality control by portal film analysis in radiotherapy for prostate cancer: a comparison between two different institutions and treatment techniques
    C Italia
    Department of Radiation Oncology, Casa di Cura S. Pio X, Milan, Italy
    Tumori 84:640-8. 1998
    ..In Institute A, the goal of minimizing small bowel irradiation and prostate motion through the aforementioned technique, which makes patient position less comfortable, did not seem to considerably increase daily setup uncertainty...
  82. ncbi request reprint Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, University Hospital of Padova, Padova, Italy
    J Clin Oncol 22:4779-86. 2004
    ..The aim of the present multicenter phase II trial, therefore, was to ascertain the efficacy of second-line carmustine (BCNU) and irinotecan chemotherapy...
  83. ncbi request reprint First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology Direzione, Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padua, Italy
    J Clin Oncol 22:1598-604. 2004
    ..The primary end point of the present multicenter phase II study was progression-free survival (PFS) at 6 months (PFS-6); secondary end points included response, toxicity, and overall survival...
  84. ncbi request reprint Primary CNS lymphomas prognosis
    Andres J M Ferreri
    J Clin Oncol 25:4322-4; author reply 4324-5. 2007
  85. ncbi request reprint Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
    René Olivier Mirimanoff
    Department of Radiation Oncology, University Hospital Lausanne, Lausanne, Switzerland
    J Clin Oncol 24:2563-9. 2006
    ..We evaluated in this trial whether the recursive partitioning analysis (RPA) retains its overall prognostic value and what the benefit of the combined modality is in each RPA class...
  86. ncbi request reprint Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?
    Michele Reni
    J Clin Oncol 22:1165-7; authir reply 1167-8. 2004
  87. ncbi request reprint A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 104:143-8. 2005
    ..No data on the role of chemotherapy in recurrent ependymal tumors are available in adults. The aim of the current study was to investigate outcomes after salvage chemotherapy in this setting...
  88. ncbi request reprint Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, Italy
    J Clin Oncol 24:4746-53. 2006
    ..The aim of this study was to evaluate correlations between 1p/19q deletions, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and response rate to TMZ in this setting...
  89. doi request reprint Oligodendroglioma
    Martin J van den Bent
    Daniel den Hoed Cancer Clinic Erasmus University Medical Center, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 66:262-72. 2008
    ..Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease...
  90. ncbi request reprint Primary central nervous system lymphoma: biological aspects and controversies in management
    Eric M Bessell
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, UK
    Eur J Cancer 43:1141-52. 2007
    ..Andres Ferreri) as well as controversies in the use of whole brain radiotherapy (WBRT) after chemotherapy (Dr. Michele Reni). The topics covered with discussants at the workshop are also summarised.
  91. pmc Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
    Alba A Brandes
    Department of Medical Oncology, Istituto Oncologico Veneto IRCCS Padova, Padova, Italy
    Neuro Oncol 8:253-60. 2006
    ..Even if no survival advantage has been demonstrated for temozolomide versus PCV, we conclude that temozolomide should be preferred because of its greater tolerability...
  92. ncbi request reprint Establishing a prognostic score for primary CNS lymphomas
    Andres J M Ferreri
    Int J Radiat Oncol Biol Phys 61:303-4; author reply 304-5. 2005
  93. ncbi request reprint Anaplastic astrocytoma in adults
    Roger Stupp
    University Hospital CHUV, Lausanne, Switzerland
    Crit Rev Oncol Hematol 63:72-80. 2007
    ..In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted...
  94. ncbi request reprint No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients
    Fernanda Martini
    Department of Morphology and Embryology, School of Medicine, University of Ferrara, Via Fossato di Mortara, 64 B, 44100 Ferrara, Italy
    Cancer Epidemiol Biomarkers Prev 13:1819-20. 2004
  95. doi request reprint Meningioma
    Christine Marosi
    University of Vienna, Austria
    Crit Rev Oncol Hematol 67:153-71. 2008
    ..Hormonal therapy with progesterone antagonists has shown modest results, while chemotherapy with hydroxyurea appears moderately active...
  96. doi request reprint Glioblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda ASL, Bologna, Italy
    Crit Rev Oncol Hematol 67:139-52. 2008
    ..At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment...